Skip to main content
Log in

Renal effects of nicardipine, a calcium antagonist, in hypertensive type 2 (non-insulin-dependent) diabetic patients with and without nephropathy

  • Originals
  • Published:
European Journal of Clinical Pharmacology Aims and scope Submit manuscript

Summary

The renal effects of oral maintenance doses of nicardipine 60–120 mg/day have been studied in 18 hypertensive patients with Type 2 (non-insulin-dependent) diabetes mellitus: 6 with normoalbuminuria (urinary albumin excretion rate, AER <20 μg · min−1, Group A); 6 with incipient nephropathy, (AER 20–200 μg · min−1, Group B); and 6 with overt nephropathy (AER >200 μg · min−1, Group C). Treatment for 4 weeks significantly lowered the systolic and diastolic blood pressures and reduced total renal vascular resistance in all three groups. Nicardipine increased renal blood flow significantly in Group C and slightly in Group B, and had no effect in Group A. Glomerular filtration rate remained unchanged in all three groups. It significantly reduced AER and the fractional clearance of albumin in Group B, whereas AER in Groups A and C was not altered. Plasma renin activity, aldosterone concentration, osmotic pressure, serum total protein and albumin concentrations and haemoglobin A1c level were similar in the control and nicardipine phases in all three groups. The results suggest that nicardipine may preserve renal function whilst having a concomitant hypotensive action in hypertensive Type 2 diabetic patients with normoalbuminuria and incipient nephropathy, and that the drug may improve renal blood flow in patients with overt nephropathy. The effect of the drug on urinary albumin excretion may deserve further investigation.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Pell S, D'Alonzo CA (1967) Some aspects of hypertension in diabetes mellitus. JAMA 202: 104–110

    Article  CAS  PubMed  Google Scholar 

  2. Baba T, Murabayashi S, Aoyagi K, Sasaki K, Imamura K, Kudo M, Takebe K (1985) Prevalence of hypertension in diabetes mellitus: Its relation to diabetic nephropathy. Tohoku J Exp Med 145: 167–173

    CAS  PubMed  Google Scholar 

  3. Mogensen CE (1982) Long-term antihypertensive treatment inhibiting progression of diabetic nephropathy. Br Med J 285: 685–688

    CAS  Google Scholar 

  4. Parving H-H, Andersen AR, Smidt UM, Svendsen PAa (1983) Early and appressive antihypertensive treatment reduces rate of decline in kidney function indiabetic nephropathy. Lancet I: 1175–1178

    Google Scholar 

  5. Pedrinelli R, Fouad FM, Tarazi RC, Bravo EL, Textor SC (1986) Nitrendipine: a calcium-entry blocker: renal and humoral effects in human arterial hypertension. Arch Intern Med 146: 62–65

    Article  CAS  PubMed  Google Scholar 

  6. Sunderrajan S, Reams G, Bauer JH (1987) Long-term renal effects of diltiazem in essential hypertension. Am Heart J 114: 383–388

    Article  CAS  PubMed  Google Scholar 

  7. van Schaik BAM, van Nistelrooy AEJ, Geyskes GG (1984) Antihypertensive and renal effects of nicardipine. Br J Clin Pharmacol 18: 57

    PubMed  Google Scholar 

  8. Reams G, Hamory A, Lau A, Bauer JH (1988) Effect of nifedipine on renal function in patients with essential hypertension. Hypertension 11: 452–456

    CAS  PubMed  Google Scholar 

  9. Hulthèn UL, Katzman PL (1988) Renal effects of acute and long-term treatment with felodipine in essential hypertension. J Hypertension 6: 231–237

    Google Scholar 

  10. Baba T, Murabayashi S, Takebe K (1989) Comparison of the renal effects of angiotensin converting enzyme inhibitor and calcium antagonist in hypertensive Type 2 (non-insulin-dependent) diabetic patients with microalbuminuria: a randomised controlled trial. Diabetologia 32: 40–44

    CAS  PubMed  Google Scholar 

  11. Baba T, Ishizaki T, Ido Y, Aoyagi K, Murabayashi S, Takebe K (1986) Renal effects of nicardipine, a calcium entry blocker, in hypertensive Type II diabetic patients with nephropathy. Diabetes 35: 1206–1214

    CAS  PubMed  Google Scholar 

  12. Baba T, Boku A, Ishizaki T, Sone K, Takebe K (1986) Renal effects of nicardipine in patients with mild-to-moderate essential hypertension. Am Heart J 111: 552–557

    Article  CAS  PubMed  Google Scholar 

  13. Mogensen CE (1987) Microalbuminuria as a predictor of clinical diabetic nephropathy. Kidney Int 31: 673–689

    CAS  PubMed  Google Scholar 

  14. Resenstock J, Raskin P (1986) Early diabetic nephropathy: assessment and potential therapeutic intervention. Diabetes Care 9: 529–545

    Google Scholar 

  15. Taylor SH, Frais MA, Lee P, Verma SP, Jackson N, Silke B (1985) Anti-hypertensive dose-response effects of nicardipine in stable essential hypertension. Br J Clin Pharmacol 20: 135S-138S

    PubMed  Google Scholar 

  16. Gomez DM (1951) Evaluation of renal resistances with special reference to changes in essential hypertension. J Clin Invest 30: 1143–1155

    CAS  PubMed  Google Scholar 

  17. Willassen Y, Ofsted J (1983) Intrarenal pressure and sodium excretion in hypertension of chronic glomerulonephritis in humans. Hypertension 5: 375–384

    CAS  PubMed  Google Scholar 

  18. Haber E, Koerner T, Page LB, Klinman B, Purnode A (1969) Application of a radioimmunoassay for angiotensin I to the physiologic measurements of plasma renin activity in normal human subjects. J Clin Endocrinol Metab 29: 1349–1355

    CAS  PubMed  Google Scholar 

  19. Ogihara T, Iinuma K, Nishi K, Arakawa Y, Takagi A, Kurata K, Miyai K, Kumahara Y (1977) A non-chromatographic non-extraction radioimmunoassay for serum aldosterone. J Clin Endocrinol Metab 45: 726–731

    CAS  PubMed  Google Scholar 

  20. Miles DW, Mogensen CE, Gundersen HJG (1979) Radioimmunoassay for urinary albumin using a single antibody. Scand J Clin Lab Invest 26: 5–11

    Google Scholar 

  21. Davis JE, McDonald JM, Jarrett L (1978) A high-performance liquid chromatography method for hemoglobin A1c. Diabetes 44: 1066–1069

    Google Scholar 

  22. Mercier DE, Feld RD, Witte DL (1978) Comparison of dewpoint and freezing point osmometry. Am J Med Tech 44: 1066–1069

    CAS  Google Scholar 

  23. Taylor SH, Silke B, Ahuja RC, Okoli R (1982) Influence of nicardipine on blood pressure at rest and on the pressor responses to cold, isometric exertion, and dynamic exercise in hypertensive patients. J Cardiovasc Pharmacol 4: 803–807

    CAS  PubMed  Google Scholar 

  24. Erne P, Bolli P, Bertel O, Hulthen UL, Kiowski W, Muller FB, Buhler F (1983) Factors influencing the hypotensive effects of calcium antagonists. Hypertension 5 [Suppl II]: II-97-10

  25. Asplund J (1985) Nicardipine hydrochloride in essential hypertension: a controlled study. Br J Clin Pharmacol 20 [Suppl]: 120S-124S

    PubMed  Google Scholar 

  26. McLeay RAB, Stallard TJ, Watson RDS, Littler WA (1983) The effect of nifedipine on arterial pressure and reflex cardiac control. Circulation 67: 1084–1090

    CAS  PubMed  Google Scholar 

  27. Kiowski W, Bertel O, Erne P, Bolli P, Hulthén UL, Ritz R, Buhler FR (1983) Hemodynamic and reflex responses to acute and chronic antihypertensive therapy with the calcium entry blocker nifedipine. Hypertension 5 [Suppl I]: I-70–74

    CAS  Google Scholar 

  28. Young MjA, Watson RDS, Littler WA (1984) Baroreflex setting and sensitivity after acute and chronic nicardipine therapy. Clin Sci 66: 233–235

    CAS  PubMed  Google Scholar 

  29. Kahn JK, Zola B, Juni JE, Vinik AI (1986) Decreased exercise heart rate and blood pressure response in diabetic subjects with cardiac autonomic neuropathy. Diabetes Care 9: 389–394

    CAS  PubMed  Google Scholar 

  30. Dyrberg TM, Benn J, Sandahl CJ, Hilsted J, Nerup J (1981) Prevalence of diabetic autonomic neuropathy measured by simple bedside tests. Diabetologia 20: 190–194

    Article  CAS  PubMed  Google Scholar 

  31. Sundkvist G, Lilja B (1985) Autonomic neuropathy in diabetes mellitus: a follow-up study. Diabetes Care 8: 129–133

    CAS  PubMed  Google Scholar 

  32. Ewing DJ, Clarke BF (1986) Diabetic autonomic neuropathy: present insights and future prospects. Diabetes Care 9: 648–665

    CAS  PubMed  Google Scholar 

  33. Loutzenhiser R, Epstein M (1985) Effects of calcium antagonists on renal hemodynamics. Am J Physiol 249: F619-F629

    CAS  PubMed  Google Scholar 

  34. Christensen C, Mogensen CE (1985) Effect of antihypertensive treatment on progression of incipient diabetic nephropathy. Hypertension 7 [Suppl]: II-109–II-113

    CAS  Google Scholar 

  35. Parving H-H, Andersen AR, Smidt UM, Hommel E, Mathiesen ER, Sevendsen PA (1987) Effect of antihypertensive treatment on kidney function in diabetic nephropathy. Br Med J 294: 1443–1447

    CAS  Google Scholar 

  36. Marre M, Leblanc H, Suarez L, Guyenne T-T, Mènard J, Passa P (1987) Converting enzyme inhibition and kidney function in normotensive diabetic patients with persistent microalbuminuria. Br Med J 294: 1448–1452

    CAS  Google Scholar 

  37. Dunn BR, Zatz R, Rennke HG, Meyer TW, Anderson S, Brenner BM (1986) Prevention of glomerular capillary hypertension in experimental diabetes mellitus obviates functional and structural glomerular injury. J Hypertens 4 [Suppl 5]: S251-S254

    CAS  Google Scholar 

  38. Hommel E, Parving H-H, Mathiesen E, Edsberg B, Neilsen MD, Giese J (1986) Effect of captopril on kidney function in insulin-dependent diabetic patients with nephropathy. Br Med J 293: 467–470

    CAS  Google Scholar 

  39. Myers BD, Deen WM, Brenner BM (1975) Effect of norepine-phrine and angiotensin II on the determinants of glomerular ultrafiltration and proximal tubule fluid reabsorption in the rat. Circ Res 37: 101–110

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Baba, T., Tomiyama, T., Murabayashi, S. et al. Renal effects of nicardipine, a calcium antagonist, in hypertensive type 2 (non-insulin-dependent) diabetic patients with and without nephropathy. Eur J Clin Pharmacol 38, 425–429 (1990). https://doi.org/10.1007/BF02336678

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02336678

Key words

Navigation